Mannkind Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mannkind Corporation

MNKD 5.490

-1.8%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	10/5/2017 9:33:33 PM
	of 84

MannKind Corp.'s stock (MNKD) rocketed Thursday on very heavy volume, putting it on track to post a third-straight 20+% gain, after the Food and Drug Administration updated prescribing information for the company's diabetes treatment to include data on rapid onset of activity. The stock ran up 32.2% in afternoon trade toward a 14-month high. Volume ballooned to 62.5 million shares, which is about 13 times the full-day average, and enough to make the stock the most actively traded on major U.S. exchanges. The stock had shot up 25.5% on Wednesday on volume of 19.0 million shares, and soared 20.5% on Tuesday on volume of 12.9 million shares. On Monday, the stock rose 7.8% on volume of 9.3 million shares, after the company revealed the FDA's update. The company did not immediately respond to a request for comment. The label now shows that first measurable effects of the inhaled insulin started in 12 minutes, with peak effects about 35 minutes to 45 minutes after and a return to baseline about 1 1/2 hours to 3 hours later. The stock has now hiked up 116% this week. It was now up 47% year to date, while the S&P 500 has gained 14%. Popped $6.51 Thur, last trade, $5.00///vol 75.8 mln

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next